Data / Form D filings / Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc.: Form D filing
Aralez Pharmaceuticals Inc., a pharmaceuticals company in Vancouver, British Columbia, Canada, filed a Form D with the SEC in 2016. The latest, on February 19, 2016, reports $75 million sold of a $75 million offering to 3 investors.
Find out what Aralez Pharmaceuticals Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2800 Park Place, 666 Burrard Street, Vancouver, British Columbia, Canada, V6C 2
- Phone
- (919) 913-1030
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Year incorporated
- 2015
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1660719
The full lists. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 19, 2016 | New notice | $75,000,000 | $75,000,000 | $0 | 3 | Feb 5, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Andrew I. Koven | Executive Officer | |
| Eric L. Trachtenberg | Executive Officer | |
| Scott J. Charles | Executive Officer | |
| Kenneth B. Lee Jr. | Director | |
| Arthur S. Kirsch | Director | |
| Adrian Adams | Executive Officer, Director | |
| Mark A. Glickman | Executive Officer | |
| Jason M. Aryeh | Director | |
| Neal F. Fowler | Director | |
| Rob F. Harris | Director | |
| James P. Tursi, M.D. | Executive Officer | |
| Seth A. Rudnick, M.D. | Director | |
| Jennifer L. Armstrong | Executive Officer | |
| F. Martin B. Thrasher | Director |
Every Form D from the week of Feb 15, 2016 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Aralez Pharmaceuticals Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.